Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 3/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099868 | 1.00 | CA2 (0.48) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL29084669 | 0.98 | CA2 (0.47) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL29238518 | 0.83 | TGFBR1 (0.39) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL163120 | 0.82 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL30300609 | 0.82 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL163119 | 0.82 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL5493514 | 0.82 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL12205353 | 0.81 | CA2 (0.49) | CA2CA4CA1MMEPRSS1 | |
| SCHEMBL14592685 | 0.81 | CA2 (0.47) | CA2CA4CA1MMEPRSS1 | |
| SCHEMBL28241652 | 0.80 | TGFBR1 (0.40) | CA2CA4CA1TGFBR1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 631 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4679086-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| EP-4679085-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20250336540-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | claimed |
| US-20250313801-A1 | SPECIFIC T CELL FOR PREVENTING OR TREATING CANCER, AND PREPARATION METHOD THEREOF | SUZHOU ERSHENG BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-10-09 | — | — | US | claimed |
| EP-4627068-A1 | FOOD AND DRUG COMPOSITION CONTAINING NOVEL ALDEHYDE DEHYDROGENASE FOR SUPPRESSING TREMOR OR MOVEMENT DISORDER | Picoentech Co., Ltd. (KR) | 2025-10-08 | — | — | EP | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2025104511-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CARDIOMYOPATHY IN A FELINE | SOCIETE DES PRODUITS NESTLE SA (CH) | 2025-05-22 | — | — | WO | claimed |
| US-7262168-B2 | Compositions providing for increased IGF-I solubility | CHIRON CORPORATION (US) | 2007-08-28 | — | — | US | claimed |
| US-20060127337-A1 | Process for relaxing keratin fibres | L'OREAL (FR) | 2006-06-15 | — | — | US | claimed |
| US-20060074011-A1 | Compositions providing for increased IGF-I solubility | CHIRON CORPORATION (US) | 2006-04-06 | — | — | US | claimed |
| US-6951842-B2 | Compositions providing for increased IGF-I solubility | CHIRON CORPORATION (US) | 2005-10-04 | — | — | US | claimed |
| US-20040209815-A1 | Compositions providing for increased IGF-I solubility | CHIRON CORPORATION | 2004-10-21 | — | — | US | claimed |
| EP-0612211-B1 | ALTERATION OF RATE AND CHARACTER OF HAIR GROWTH | GILLETTE CO (US) | 2002-06-05 | — | — | EP | claimed |
| US-5444090-A | Applying a synthetase inhibitor | GILLETTE COMPANY, THE, (A DELAWARE CORPORATION) | 1995-08-22 | — | — | US | claimed |
| EP-0612211-A4 | ALTERATION OF RATE AND CHARACTER OF HAIR GROWTH. | HANDELMAN JOSEPH H (US) | 1994-12-07 | — | — | EP | claimed |
| EP-0612211-A1 | ALTERATION OF RATE AND CHARACTER OF HAIR GROWTH | HANDELMAN, Joseph H. (US) | 1994-08-31 | — | — | EP | claimed |
| WO-1993008687-A1 | ALTERATION OF RATE AND CHARACTER OF HAIR GROWTH | HANDELMAN JOSEPH H (US) | 1993-05-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313801-A1 | SPECIFIC T CELL FOR PREVENTING OR TREATING CANCER, AND PREPARATION METHOD THEREOF | CD4, CD69, CD47 | CA2 2678/4885CA4 2197/4885CA1 1486/4885 |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | CA2 3043/4885CA4 2768/4885CA1 2585/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | CA2 211/4885CA4 896/4885CA1 1008/4885 |
| US-20060127337-A1 | Process for relaxing keratin fibres | KRT18, TPM4, MYLK | CA2 198/4885CA4 487/4885CA1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.